1. Home
  2. GGR vs ACRV Comparison

GGR vs ACRV Comparison

Compare GGR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$3.91

Market Cap

83.3M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.96

Market Cap

67.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
ACRV
Founded
2011
2018
Country
Taiwan
United States
Employees
1416
N/A
Industry
Auto Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
67.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
GGR
ACRV
Price
$3.91
$1.96
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
21.5K
415.4K
Earning Date
05-21-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.07
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$1.20
52 Week High
$6.21
$3.56

Technical Indicators

Market Signals
Indicator
GGR
ACRV
Relative Strength Index (RSI) 39.64 65.74
Support Level $3.71 $1.62
Resistance Level $4.20 $2.02
Average True Range (ATR) 0.19 0.12
MACD -0.02 0.05
Stochastic Oscillator 12.98 74.07

Price Performance

Historical Comparison
GGR
ACRV

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: